[140 Pages Report] The global cellular health screening market is estimated to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0% during the forecast period. Factors such as the increasing adoption of telomere performance programs for leading a healthy life; growing importance of healthy life expectancy (HALE); rising government focus towards preventive healthcare; rising geriatric population and resultant growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach; and the increasing burden of chronic diseases are expected to drive the growth of this market. On the other hand, problems associated with the transport of samples and differences in the cost of test kits offered by different companies are expected to restrain the growth of this market during the forecast period.

North America is expected to account for the largest share of the market, followed by Europe. However, Asia is projected to register the highest CAGR during the forecast period. The high growth of the Asian market can be attributed to the rising geriatric population, increasing burden of chronic diseases, expansion opportunities for market players, and growing number of initiatives to create awareness about healthy lifestyles and preventive healthcare in several Asian countries.

The report segments market based on type, sample type, sample collection type and region.

On the basis of type, the global market is segmented into single test panels and multi test panels. Cellular health screening comprises four major tests, namely, telomere tests, oxidative stress tests, inflammation tests, and heavy metals tests. These are risk assessment tests that help detect biological age, cellular toxicity, and the risk of diseases. These test kits are categorized into single and multi-test panels. In every test, there are different Biomarkers that are tested to draw a conclusion. Single test panels are used to examine individual biomarkers for specific results, while tests for a combination of cellular biomarkers are carried out using multi-test panels/kits. The single test panels segment is expected to dominate the market in 2017, and this trend is expected to continue during the forecast period. However, the multi-test panels segment is estimated to register a relatively higher growth rate between 2017 and 2022.

The global market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (US), Telomere Diagnostics (US), Life Length (Spain), Quest Diagnostics (US), Repeat Diagnostics (Canada), SpectraCell Laboratories (US), Zimetry LLC (US), Cell Science Systems (US), Titanovo, Inc. (US), Segterra, Inc. (US), LabCorp Holdings (US), BioReference Laboratories (US), Immundiagnostik AG (Germany), and Cleveland HeartLab, Inc. (US).

Major Market Developments:

In 2016, Telomere Diagnostics launched TeloYears, its new telomere test.

In 2015, SpectraCell announced the expansion of its specialized testing menu to include several new diagnostic panels for cardiometabolic biomarkers, pre-diabetic screening, male and female hormone panels, thyroid, and adrenal function and cardiovascular-related genetic tests.

In 2016, Life Length partenered with Eastern Biotech & Life Sciences to launch telomere tests in GCC countries.

In 2015, Titanovo launched an at-home, saliva-based telomere testing kit.

To know about the assumptions considered for the study, download the pdf brochure

Stakeholders:

Cellular health screening service providers

Clinical laboratories

Healthcare institutions (hospitals and outpatient clinics)

Academic institutes and universities

Distributors and suppliers of cellular health screening kits and services

Scope of the Report

This report categorizes the global cellular health screening market into following segments and subsegments.

By Type

Single-test Panels Telomere Tests Oxidative Stress Tests Inflammation Tests Heavy Metal Tests

Multi-test Panels

By Sample Type

Blood

Others Samples*

By Sample Collection Site

At-home

In office

Other Sites**

By Region

North America

Europe

Asia

RoW

Note: 1. *Other samples include body fluids such as urine, saliva, and serum

2. **Other sites include hospitals and diagnostic laboratories.

Critical Questions which the report answers:

Which regions will provide the high growth opportunities?

Which type market will dominate in future?

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs.

The following customization options are available for this report.

Company Information

Detailed analysis and profiling of additional market players (up to 5)

The global market is expected to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0% during the forecast period.

A number of factors such as increasing adoption of telomere performance programs for leading a healthy life; growing importance of healthy life expectancy (HALE); rising government focus towards preventive healthcare; rising geriatric population and resultant growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach; and the increasing burden of chronic diseases are driving the demand for global cellular health screening. On the other hand, problems associated with the transport of samples and differences in the cost of test kits offered by different companies are some of the factors that may hinder the overall growth of this market.

This report segments the global market into type, sample type, sample collection site, and region. On the basis of type, the global market is segmented single test panels and multi-test panels. The multi-test panels segment is expected to grow at the highest CAGR during the forecast period. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.

The global market, by sample type is segmented into blood samples and other samples. In 2017, the blood samples segment is expected to account for the largest share of the market. The large share and high growth of this segment can primarily be attributed to the advantages associated with the use of blood samples, such as the accuracy and reliability of test results.

By sample collection site, the global market is segmented into at-home, in-office, and other sample collection sites. In 2017, the at-home segment is expected to account for the largest share of the market. The large share of this segment can be attributed to the availability of diagnostic and therapeutic products that can be used by patients at home without assistance from healthcare professionals.

In 2017, North America is expected to dominate the global market. Factors such as growing government focus towards preventive healthcare, increasing burden of chronic diseases, increasing research activities, rising geriatric population, and growing number of local players operating in the region are expected to drive the growth of this regional segment.

Asia is projected to register the highest CAGR during the forecast period. The high growth of the Asian market can be attributed to the rising geriatric population, increasing burden of chronic diseases, expansion opportunities for market players, and growing number of initiatives to create awareness about healthy lifestyles and preventive healthcare in several Asian countries

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

At-home segment site dominates the market by sample collection site

At-home sample collection

The Home Healthcare market is witnessing rapid growth across the globe. This can primarily be attributed to the availability of diagnostic and therapeutic products that can be used by patients at home without assistance from healthcare professionals. Moreover, home healthcare is convenient for patients, and it helps save time and costs incurred in visiting healthcare professionals in hospitals and clinics. With the growing demand for self-medication and self-testing, several companies in the market have launched kits that can directly be used by patients. These kits are easy to handle and can be used without any assistance.

In-office sample collection

Though there is a growing trend of self-medication and self-testing, in several cases, it is essential to have the assistance of physicians for diagnostic and therapeutic purposes. As a result, several market players offer their testing services only under the guidance of physicians. Though several cellular health screening tests are provided directly to patients, certain companies still prefer providing their services through a physician to ensure patient safety and the accuracy of the sample collection process

Other Sites

Hospitals and diagnostic laboratories are the other sites that can be considered as safe locations for sample collection. Diagnostic tests of the in-patient population are generally conducted in hospitals. Moreover, some physicians recommend reliable diagnostic laboratories for sample collection and testing processes. As both hospitals as well as diagnostic laboratories have trained personnel, it is safe and easy for patients to get tested at these facilities

The global market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (US), Telomere Diagnostics (US), Life Length (Spain), Quest Diagnostics (US), Repeat Diagnostics (Canada), SpectraCell Laboratories (US), Zimetry LLC (US), Cell Science Systems (US), Titanovo, Inc. (US), Segterra, Inc. (US), LabCorp Holdings (US), BioReference Laboratories (US), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (US).